Acrivon Therapeutics, Inc. current report, 14 November 2022

Full document

Business Context and Reporting Period

Acrivon Therapeutics, Inc. filed a Form 8-K dated November 14, 2022, with the report signed November 17, 2022. The filing relates to the closing of the company’s initial public offering and a concurrent private placement, as well as related corporate-governance documents.

Key Financial and Capitalization Matters

  • The company agreed to issue and sell 400,000 shares of common stock to Chione Limited in a private placement.
  • Aggregate gross proceeds were $5.0 million, before placement-agent fees.
  • The private placement closed on November 17, 2022.
  • The filing does not provide revenue, profit, cash-flow, margin, debt, cash-balance, or liquidity figures.

Material Changes Versus the Prior Comparable Period

  • The filing text does not provide comparative-period financial information.
  • The material reported changes are the completion of the private placement and the effectiveness of the company’s amended and restated certificate of incorporation and bylaws in connection with the IPO.

Guidance, Outlook, Risks, and Unusual Items

  • The shares issued in the private placement were not registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption.
  • The company is relying on the private-placement exemption under Section 4(a)(2) of the Securities Act.
  • The share purchase agreement includes customary representations, warranties, closing conditions, indemnification obligations, other agreements, and termination provisions.
  • The filing does not provide management guidance, clinical or operational outlook commentary, or additional contingencies.

Important Facts for Investors to Verify

  • Confirm the November 17, 2022 closing date and the issuance of 400,000 shares to Chione Limited.
  • Verify the $5.0 million gross proceeds and determine the net proceeds after placement-agent fees and other expenses.
  • Review the Share Purchase Agreement filed as Exhibit 99.1 for contractual rights, obligations, indemnification, and termination provisions.
  • Review the amended and restated certificate of incorporation and bylaws filed as Exhibits 3.1 and 3.2.
  • Assess the resulting dilution and updated shares outstanding using the company’s IPO and subsequent capitalization disclosures.